

Investor Relations | Hologic

Hologic's ThinPrep® Selected as Exclusive Pap Test for Netherlands Cervical Cancer Screening Program

--ThinPrep Pap Test will be only collection vial and reflex cytology test at national laboratories--

MARLBOROUGH, MA September 8, 2016 – Hologic, Inc. (Nasdaq: HOLX) announced today that the Company's ThinPrep® Pap test will be used exclusively for HPV sample collection and reflex cytology in its national screening program for cervical cancer.

Beginning in January 2017, ThinPrep will serve as the collection vial for all HPV testing and as the only test for reflex cytology at all national labs for a period of five years.

“Over the past 20 years, ThinPrep has become the gold standard for liquid-based cytology, with more than 650 million tests performed worldwide,” said Joao Malagueira, VP Sales Diagnostics, International, Divisional President/GM at Hologic. “We are very pleased that the Dutch government and national laboratories have chosen this well-established and highly regarded technology for their program.”

In the United States, ThinPrep is the only liquid-based Pap test that is FDA-approved for testing for Chlamydia/Gonorrhea, human papillomavirus (HPV) and Trichomonas straight out of the vial. Moreover, the ThinPrep Pap Test is the only Pap test with FDA-approved labeling supported by multiple peer-reviewed publications showing increased glandular disease detection.¹

About Hologic

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The company's core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure. For more information on Hologic, visit www.hologic.com.

Hologic Forward-Looking Statements

This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic's diagnostic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient. The actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any

change in expectations or any change in events, conditions or circumstances on which any such statements are based.

Hologic, The Science of Sure, and ThinPrep are trademarks (or registered trademarks) of Hologic, Inc. in the United States and/or other countries.

¹ *Thin Prep Package insert. MAN-02060-002 Rev. 001*

Hologic Investor Contact

Michael Watts

Vice President, Investor Relations and Corporate Communications

(858) 410-8588

michael.watts@hologic.com

Hologic Media Contact

Jane Mazur

Senior Director, Divisional Communications

+1 (585) 355-5978

jane.mazur@hologic.com

<http://investors.hologic.com/news?item=618>